Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.

Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data ↗

September 08, 2026

Via Benzinga

Performance

52-Week Range 77.0% below 52-week high

21.80

20.7352W Low 94.9052W High

1 Week 8.5% below 1-week high

20.731W Low 23.831W High

Structure Therapeutics Inc. - American Depositary Shares (GPCR) traded between $20.73 and $94.90 over the past 52 weeks and last traded at $21.80, 77.0% below its 52-week high. Over the past week it ranged between $20.73 and $23.83.

Past 12 Months

+3.4%

-40.9%

-57.1%

-53.6%

-68.0%

-18.2%

1W +$0.72

1M -$15.11

3M -$29.00

6M -$25.22

YTD -$46.32

1Y -$4.86

GPCR was -18.2% over the past year, -53.6% over six months, -68.0% year to date, +3.4% in the last week.

12 Months vs Market

GPCR

-18.2%

DIA

+12.2%

SPY

+14.2%

QQQ

+16.8%

IWM

+13.3%

Over the past 12 months GPCR returned -18.2% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +16.8% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 0.23× 3-mo avg

Today 250,110 3-mo avg 1.1M

1.1M

1.4M

1.1M

935.7K

YTD

972.0K

1.1M

GPCR most recently traded 250,110 shares against a 3-month average daily volume of 1.1M.

More News

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

September 08, 2026

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

September 03, 2026

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 06, 2026

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

June 05, 2026

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

May 26, 2026

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

Monashee Scales Back Its Bet on Structure Therapeutics ↗

May 20, 2026

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗

May 17, 2026

Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗

May 10, 2026

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 07, 2026

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

April 27, 2026

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗

April 17, 2026

Via MarketBeat

April 14, 2026

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

April 03, 2026

Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring

April 02, 2026

Main Street’s Revenge: The Great Rotation of 2026 Rewrites Market History

March 26, 2026

The Great Rotation: Small-Caps Seize Market Leadership in Historic 2026 Breakout

March 25, 2026

The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026

March 24, 2026

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

3 Companies at the Forefront of the GLP-1 Pill Wars ↗

March 16, 2026

Via MarketBeat

March 16, 2026

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026